References
- [Internet]. . Who.int. 2020 [cited 2020 Jun 25]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200608-covid-19-sitrep-140.pdf?sfvrsn=2f310900_2
- Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.
- Cummings M, Baldwin M, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763-1770.
- Bhatraju P, Ghassemieh B, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seatle Region — Case Series. N Engl J Med. 2020;382(21):2012-2022.
- Berlin DA, Gulick RM, Martinez FJ Severe Covid-19. Published online May 15th, 2020 DOI: https://doi.org/10.1056/NEJMcp2009575
- Tabrizi M, Schinco M, Tepas J, et al. Inhaled epoprostenol improves oxygenation in severe hypoxemia. J Trauma Acute Care Surg. 2012;73(2):503-506.
- Alessandri F, Pugliese F, Ranieri V. The Role of Rescue Therapies in the Treatment of Severe ARDS. Respir Care. 2017;63(1):92101.
- Duan E, Adhikari N, D’Aragon F, et al. Management of Acute Respiratory Distress Syndrome and Refractory Hypoxemia. A Multicenter Observational Study. Ann Am Thorac Soc. 2017;14(12):1818-1826.
- Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome. N Engl J Med. 2000;342(18):1301-1308.
- Wiedemann H, Wheeler A, Bernard G. Comparison of two fluid-management strategies in acute lung injury. J Vasc Surg. 2006;44(4):909.
- Briel M, Meade M, Mercat A, et al. Higher versus lower positive end-expiratory pressure in acute lung injury and acute respiratory distress syndrome: systematic review and individual patient data meta-analysis. Crit Care. 2010;14(Suppl 1): P182.
- Alhazzani W, Møller M, Arabi Y, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020;48(6):e440-e469.
- Fuller B, Mohr N, Skrupky L, Fowler S, Kollef M, Carpenter C. The Use of Inhaled Prostaglandins in Patients With ARDS. Chest. 2015;147(6):1510-1522.
- Dzierba A, Abel E, Buckley M, Lat I. A Review of Inhaled Nitric Oxide and Aerosolized Epoprostenol in Acute Lung Injury or Acute Respiratory Distress Syndrome. Pharmacotherapy. 2013;34(3):279-290.
- Torbic H, Szumita P, Anger K, et al. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients. J Crit Care. 2013;28(5):844-848.
- Searcy R, Morales J, Ferreira J, Johnson D. The role of inhaled prostacyclin in treating acute respiratory distress syndrome. Ther Adv in Respir Dis. 2015;9(6):302-312.
- Dellinger R, Zimmerman J, Taylor R, et al. Efects of inhaled nitric oxide in patients with acute respiratory distress syndrome. Crit Care Med. 1998;26(1):15-23.
- Fallah F. Recent Strategies in Treatment of Pulmonary Arterial Hypertension, A Review. Glob J of Health Sci. 2015Jan25;7(4).
- De Wet CJ, Afleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, efective, and afordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2004;127(4):1058–67.
- Epoprostenol [package insert]. . Federal Drug Administration: GlaxoSmithKline; 1995.
- Liu X, Wang X-J. Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genomics. 2020:20;47(2):119-121.
- Rismanbaf A. Potential Treatments for COVID-19; a Narrative Literature Review. Arch Acad Emerg Med. 2020;8(1).
- Farag A, Wang P, Ahmed M, Sadek H. Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning (Version 2). ChemRxiv. Published online 2020; DOI: doi.org/10.26434/chemrxiv.12003930.v2
- COVID View, Key Updates for Week 22 [Internet]. Centers for Disease Control and Prevention. 2020 [accessed 2020 June 7th]. Available from: https://www.cdc.gov/coronavirus/2019ncov/covid-data/covidview/index.html
- Feng Y, Amoateng-Adjepong Y, Kaufman D, Gheorghe C, Manthous C. Age, Duration of Mechanical Ventilation, and Outcomes of Patients Who Are Critically Ill. Chest. 2009;136(3):759-764.
- Ware L, Mathay M. The Acute Respiratory Distress Syndrome. N Engl J Med. 2000;342(18):1334-1349.
- Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admited to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574.
- Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154(6):16711677.
- Bernard G, Artigas A, Brigham K, et al. Report of the American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes and clinical trial coordination. Intensive Care Med. 1994;20(3):225-232.
- DeGrado J, Szumita PM, Schuler BR, et al. Evaluation of the Eficacy and Safety of Inhaled Epoprostenol and Inhaled Nitric Oxide for Refractory Hypoxemia in Patients with Coronavirus Disease 2019. Crit Care Explore. 2020;2(10):e0259
- Sonti R, Pike CW, Cobb N. Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19. J Intensive Care Med. 2021;36(3):327-333.